https://www.nasdaq.com/press-release/anaptysbio-to-present-at-the-40th-annual-j.p.-morgan-healthcare-conference-2022-01-05
https://www.nasdaq.com/press-release/anaptysbio-announces-appointment-of-daniel-faga-to-board-of-directors-2021-11-29
https://www.nasdaq.com/press-release/anaptysbio-to-present-at-the-2021-jefferies-london-healthcare-conference-2021-11-15
https://www.nasdaq.com/press-release/anaptysbio-announces-positive-rosnilimab-healthy-volunteer-phase-1-top-line-data-2021
https://www.nasdaq.com/press-release/anaptysbio-announces-third-quarter-2021-financial-results-and-provides-pipeline
https://www.nasdaq.com/press-release/anaptysbio-announces-agreement-to-monetize-portion-of-jemperli-royalties-for-%24250
https://www.nasdaq.com/press-release/anaptysbio-presents-updated-data-from-imsidolimab-phase-2-gallop-trial-in-generalized
https://www.nasdaq.com/press-release/anaptysbio-to-participate-in-the-h.c.-wainwright-23rd-annual-global-investment
https://www.nasdaq.com/press-release/fda-grants-accelerated-approval-of-jemperli-dostarlimab-gxly-for-dmmr-recurrent-or
https://www.nasdaq.com/press-release/anaptysbio-announces-second-quarter-2021-financial-results-and-provides-pipeline
https://www.nasdaq.com/press-release/anaptysbio-to-present-at-the-2021-jefferies-virtual-healthcare-conference-2021-05-27
https://www.nasdaq.com/press-release/anaptysbio-announces-first-quarter-2021-financial-results-and-provides-pipeline
https://www.nasdaq.com/press-release/european-commission-approves-jemperli-dostarlimab-the-first-anti-pd-1-therapy
https://www.nasdaq.com/press-release/fda-approves-jemperli-dostarlimab-gxly-for-dmmr-endometrial-cancer-2021-04-22
https://www.nasdaq.com/press-release/anaptysbio-announces-appointment-of-oleg-nodelman-to-board-of-directors-2021-04-12
https://www.nasdaq.com/press-release/anaptysbio-reports-imsidolimab-poplar-phase-2-clinical-trial-in-moderate-to-severe
https://www.nasdaq.com/press-release/anaptysbio-announces-fourth-quarter-and-full-year-2020-financial-results-and-provides
https://www.nasdaq.com/press-release/anaptysbio-to-present-at-the-39th-annual-j.p.-morgan-healthcare-conference-2021-01-07
https://www.nasdaq.com/press-release/anaptysbio-to-present-at-the-2020-jefferies-london-virtual-healthcare-conference-2020
https://www.nasdaq.com/press-release/anaptysbio-announces-third-quarter-2020-financial-results-and-provides-pipeline
https://www.nasdaq.com/press-release/anaptysbio-and-glaxosmithkline-amend-strategic-immuno-oncology-collaboration-2020-10
https://www.nasdaq.com/press-release/anaptysbio-reports-positive-topline-data-from-gallop-phase-2-clinical-trial-of
https://www.nasdaq.com/press-release/anaptysbio-to-present-at-the-2020-cantor-global-virtual-healthcare-conference-2020-09
https://www.nasdaq.com/press-release/shuman-glenn-stecker-investigates-anaptysbio-inc.-2020-08-24
https://www.nasdaq.com/press-release/anaptysbio-announces-second-quarter-2020-financial-results-and-provides-pipeline
https://www.nasdaq.com/press-release/anaptysbio-reports-top-line-data-from-interim-analysis-of-eclipse-phase-2-clinical
https://www.nasdaq.com/press-release/anaptysbio-to-present-at-the-2020-wedbush-pacgrow-healthcare-conference-2020-08-05
https://www.nasdaq.com/press-release/anaptysbio-appoints-dr.-paul-f.-lizzul-as-chief-medical-officer-2020-07-31
https://www.nasdaq.com/press-release/anaptysbio-expands-executive-leadership-team-2020-07-15
https://www.nasdaq.com/press-release/anaptysbio-announces-orphan-drug-designation-of-imsidolimab-for-treatment-of
https://www.nasdaq.com/press-release/anaptysbio-announces-first-quarter-2020-financial-results-and-provides-pipeline
https://www.nasdaq.com/press-release/anaptysbio-announces-fourth-quarter-and-full-year-2019-financial-results-and-provides
https://www.nasdaq.com/press-release/anaptysbio-to-present-at-the-cowen-and-company-40th-annual-health-care-conference
https://www.nasdaq.com/press-release/anaptysbio-to-present-at-j.p.-morgan-annual-healthcare-conference-2020-01-08
https://www.nasdaq.com/press-release/anaptysbio-announces-third-quarter-2019-financial-results-and-provides-pipeline
https://www.nasdaq.com/press-release/anaptysbio-reports-etokimab-atlas-phase-2b-clinical-trial-in-moderate-to-severe
